DULAGLUTIDE (Trulicity) prior authorization at Highmark
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Highmark requires GLP-1 Receptor Agonist prior-authorization documentation for DULAGLUTIDE (Trulicity): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Highmark reviews DULAGLUTIDE (Trulicity) prior authorizations against its medical policy for GLP-1 Receptor Agonist. Highmark-specific context: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in GLP-1 Receptor Agonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Highmark's medical policy URL referenced in the cover letter
Highmark's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Prior auth on biologics
- PA on advanced imaging
- OON balance bills
DULAGLUTIDE (Trulicity)-specific denial patterns and context
Across payers (not just Highmark), DULAGLUTIDE (Trulicity)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring semaglutide or tirzepatide first (clinically-preferred per ADA 2024)
- Non-formulary tier 4 specialty
- Quantity limit on weekly pen
- Prior auth requiring A1C ≥7.5% documentation
Brand: Trulicity. Once-weekly GLP-1 for T2D. REWIND trial established CV risk reduction in T2D with or without established CV disease. Often displaced as plans prefer semaglutide or tirzepatide.
Manufacturer patient-assistance program: Lilly Cares Foundation — relevant when a Highmark denial sticks and the patient needs bridge access while appealing.
How Highmark approaches GLP-1 receptor agonists PAs
Highmark's GLP-1 receptor agonists reviewer typically requires documented trial of metformin and/or SGLT2 inhibitor, A1C still ≥7.5%, and (for weight-management indications) BMI documentation matching the FDA label before approving DULAGLUTIDE (TRULICITY). Pharmacy-benefit review for DULAGLUTIDE (TRULICITY) at Highmark is routed through Express Scripts. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Plans including Highmark commonly distinguish T2D-indication PAs (Ozempic, Mounjaro, Trulicity) from weight-management-indication PAs (Wegovy, Zepbound, Saxenda) — the second path triggers benefit-exclusion review under the plan's anti-obesity-medication carve-out language. Highmark is domiciled in PA, so unresolved appeals escalate to the PA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Operates BCBS in PA (western), WV, DE, NY (western).
If the PA is denied
Highmark gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.highmark.com/provider) with the same packet plus a peer-reviewed citation supporting DULAGLUTIDE (Trulicity)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Highmark denial on DenialHelp.
Contact Highmark
- Provider portal: https://www.highmark.com/provider
Frequently asked questions
What documentation does Highmark need for DULAGLUTIDE (Trulicity) prior auth?
Highmark's typical PA packet for DULAGLUTIDE (Trulicity): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For GLP-1 Receptor Agonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Highmark?
Standard DULAGLUTIDE (Trulicity) PA decisions at Highmark: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Highmark most often reject DULAGLUTIDE (Trulicity) for?
Across Highmark's book the common rejection patterns include: Prior auth on biologics; PA on advanced imaging; OON balance bills. For DULAGLUTIDE (Trulicity) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Why does Highmark require specific BMI documentation for DULAGLUTIDE (TRULICITY)?
Highmark's GLP-1 prior-auth policy distinguishes T2D-indication submissions (A1C-based criteria) from weight-management-indication submissions (BMI ≥30, or ≥27 with weight-related comorbidity, matching the FDA label). For weight-management DULAGLUTIDE (TRULICITY) the reviewer also screens for the plan's anti-obesity-medication exclusion — submit the chart note with BMI, weight-related comorbidity (HTN, dyslipidemia, T2D, OSA, OA), and either (a) ≥6 months of documented lifestyle intervention or (b) a documented reason intensive lifestyle was inappropriate. 30-day standard decision, 180-day appeal window. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Highmark fully-insured policies sits with the PA insurance department.
How do I prep for a peer-to-peer with Highmark on DULAGLUTIDE (Trulicity)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the DULAGLUTIDE (Trulicity) PA packet
Open ApprovalHelp — generate a DULAGLUTIDE (Trulicity) prior-auth packet tailored to Highmark's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com